Biotech companies at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

68 biotech companies are at ENA 2026 — 93 presentations on the program and 1 with a booth in the exhibit hall. Most represented: Arcus Biosciences (3 on the program), Acrivon Therapeutics (2 on the program), Avistone Biotechnology (2 on the program). 20 of them have their own page in this guide. As of Oct 13, 2026.

All 254 organizations at ENA 2026 →

Showing 1–13 of 68 organizations

Organization	ENA 2026 Attendance
Arcus Biosciences Hayward, CA
arcusbio.com Biotech Develops cancer medicines including the HIF-2 alpha inhibitor casdatifan and immunotherapy combinations.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers Selective targeting of AXL overcomes inherent resistance to RAS targeting therapies Targeted agents Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies A HIF-2α activity signature highlights the therapeutic potential of casdatifan as an HCC treatment Biomarkers Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Hypoxia-inducible factor-2α inhibition with casdatifan combines with checkpoint receptor modulation to enhance tumor control Targeted agents
Acrivon Therapeutics Watertown, MA
acrivon.com Biotech Clinical-stage oncology company using its AP3 phosphoproteomics platform to discover drugs and match them to responsive patients.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: DNA Repair Modulation (e.g. PARP, CHK, ATR, ATM) Acrivon Predictive Precision Proteomics (AP3)-phosphoproteomics uncovers differential mechanisms driving superior activity of ACR-2316, a novel, clinical-stage WEE1/PKMYT1 inhibitor over clinical-stage WRN helicase inhibitors Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs Rapid discovery of selective oral CDK11 inhibitors inducing complete tumor regression in acute myeloid leukemia models using Acrivon Predictive Precision Proteomics (AP3) drug discovery platform Drug design
Avistone Biotechnology Beijing, China
avistonebio.com Biotech Commercial-stage oncology company with the MET inhibitor vebreltinib marketed in China and brain-penetrant EGFR and HER2 inhibitors in development.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents ANS05, a Novel Irreversible Brain-penetrant HER2 TKI, Targets Clinically Relevant HER2 Alterations and Demonstrates Potent Broad-Spectrum Preclinical Activity Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents ANS02, a Novel, Non-covalent, Brain-penetrant EGFR TKI, Overcomes Clinically Relevant Resistance Mutations and Demonstrates Broad Preclinical Activity in EGFR-Mutant NSCLC Models Targeted agents
BioNTech Mainz, Germany
biontech.com Biotech Immunotherapy company developing mRNA vaccines, cell therapies, bispecific antibodies and antibody-drug conjugates for cancer.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Preclinical evaluation of BNT329, a novel antibody-drug-conjugate targeting the sialyl Lewis A antigen CA19-9 ADCs & radioligands Plenary Fri Nov 20 11:15am–12pm Keynote lecture: Immunotherapy innovations Immuno-oncology
Edison Oncology Menlo Park, CA
edisononcology.com Biotech Clinical-stage company developing small-molecule cancer drugs, including the brain-penetrant pan-ErbB inhibitor EO1001 and elesclomol.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents EO3001 (elesclomol), a copper ionophore that exploits ferredoxin-1 (FDX1) to drive cuproptosis in ARID1A-mutant solid tumors: preclinical rationale and design of an all-comer Phase I/II dose-escalation study with prospective ARID1A biomarker stratification Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Phase 1–2a Dose Escalation and Expansion of EO1001, an Oral Brain-Penetrant Pan-ErbB Inhibitor, in Advanced ErbB-Driven Solid Tumors: Safety, Pharmacokinetics, and Preliminary Clinical Activity Following Completion of Enrollment Targeted agents
Iambic Therapeutics San Diego, California
iambic.ai Biotech Clinical-stage biotech using AI-driven drug discovery to develop small-molecule cancer therapies.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents IAM-C1, a potent and selective dual CDK2/CDK4 inhibitor, demonstrates robust antitumor activity and a favorable preclinical tolerability profile Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs IAM-K2, a Novel, Brain-penetrant KIF18A Inhibitor for Targeting Chromosomal Instability in Cancer Drug design
Immuneering Cambridge, Massachusetts
immuneering.com Biotech Clinical-stage oncology company developing atebimetinib, a deep cyclic MEK inhibitor for MAPK-driven cancers.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies Atebimetinib, a deep cyclic inhibitor of MEK, combined with chemotherapy: preclinical rationale for treatment of anaplastic thyroid cancer (ATC) Biomarkers Talk Thu Nov 19 2:20–2:25pm Part of Posters in the Spotlight, session 1 Patient-aligned 3D tumor models identify biomarker-enriched atebimetinib (IMM-1-104) combination strategies in pancreatic ductal adenocarcinoma Preclinical models · Targeted agents
Pyxis Oncology Boston, MA
pyxisoncology.com Biotech Clinical-stage company developing antibody-drug conjugates, including micvotabart pelidotin targeting extradomain-B of fibronectin.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates In vitro characterization of the mechanism of action of micvotabart pelidotin, an antibody-drug conjugate targeting extradomain-B of fibronectin ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Micvotabart pelidotin in combination with EGFR-targeted therapy improves duration of response in HNSCC PDX models ADCs & radioligands
Ryvu Therapeutics Kraków, Poland
ryvu.com Biotech Clinical-stage company developing small-molecule cancer drugs, including kinase inhibitors and synthetic lethality programs.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates RVU602: A Non-TOP1/Non-Tubulin Cytotoxic and Immunomodulatory Payload for Next-Generation ADCs ADCs & radioligands Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Mapping Hidden Vulnerabilities in Genetically Stratified Colorectal Cancer with ONCO Prime Targeted agents
EL Earendil Labs
Biotech AI-driven biologics developer building bispecific and multispecific antibodies and antibody-drug conjugates.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Development and Preclinical Characterization of a First-in-Class Nectin-4/HER2 Bispecific Antibody-Drug Conjugate with a Topoisomerase I Inhibitor Payload for Solid Tumors ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Engineering and development of a novel bispecific ADC targeting EGFR and FGFR2b ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates An AI-Guided Biparatopic B7H3-Targeting ADC Demonstrates Enhanced Preclinical Efficacy ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates An AI-Guided Biparatopic DLL3-Targeting ADC Demonstrates Enhanced Preclinical Efficacy ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates A Novel Bispecific TROP2/PD-L1 Antibody-Drug Conjugate Demonstrates Potent Synergistic Antitumor Activity and a Favorable Safety Profile ADCs & radioligands
SH Shanghai Hongcheng Biopharma Shanghai, China
Biotech Biotech developing antibody-drug conjugates, T-cell engagers and immune-stimulating antibody conjugates for cancer.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Development of a Novel TAG-72 Targeting ADC with a proprietary pan-RAS(ON) molecular glue payload ADCs & radioligands Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New therapies in immuno oncology A novel biparatopic DLL3 T Cell Engager utilizing a cis-binding CD58 demonstrated superior potency and remarkable safety profile Immuno-oncology Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New therapies in immuno oncology Targeted cDC1 Activation via Anti-CLEC9A ISAC Potentiates Anti-Tumor Immunity Immuno-oncology Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New therapies in immuno oncology A novel FcRL5-targeting T-cell engager with a cis-binding CD58 costimulatory arm enhances anti-tumor efficacy while mitigating CRS and T-cell fratricide Immuno-oncology
Arvinas New Haven, CT
arvinas.com Biotech Develops PROTAC protein degraders, including vepdegestrant and the KRAS G12D degrader ARV-806.	Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With Chemotherapy in KRAS G12D–Mutated Pancreatic Cancer Models Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies (mAbs) in KRAS G12D–Mutated Colorectal Cancer (CRC) Models Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With the RAS-ON Multi-Selective Inhibitor Daraxonrasib in KRAS G12D–Mutated Models Targeted agents
Avammune Bengaluru, India
avammune.com Biotech Develops small-molecule cancer therapies, including ADAR1 and ENPP1 inhibitors that boost immune responses.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New therapies in immuno oncology Discovery of First-in-Class Zα-Domain-Selective ADAR1 p150 Inhibitors AVA-ADR-568/598 with Oral Bioavailability and Anti-PD-1 Combination Efficacy in Interferon-High Melanoma Models Immuno-oncology Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies Pharmacologic Inhibition of ENPP1 by AVA-NP-695 Synergizes with DNA Damage Response Inhibitors in Preclinical Models of Osteosarcoma and Ewing Sarcoma Targeted agents